SEP 226330

Drug Profile

SEP 226330

Alternative Names: SEP-0226330; SEP-226330

Latest Information Update: 07 Jul 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sepracor
  • Developer Sepracor; Sunovion Pharmaceuticals
  • Class Antiparkinsonians
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Parkinson's disease; Restless legs syndrome

Most Recent Events

  • 12 Oct 2010 Sepracor is now called Sunovion Pharmaceuticals
  • 22 Oct 2009 Preclinical trials in Parkinson's disease in USA (PO)
  • 21 Oct 2009 Pharmacodynamics data from primate studies in Parkinson's disease presented at the 39th Annual Meeting of the Society for Neuroscience (SfN- 2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top